Effect of nifedipine with and without sildenafil citrate for the management of preterm labor in pregnant women: A randomized clinical trial

other OA: gold CC-BY-NC-4.0
AI-generated summary by claude@2026-06, 2026-06-09

Adding sildenafil citrate to nifedipine for preterm labor increased gestational age and improved neonatal outcomes compared to nifedipine alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Preterm labor is one of the main causes of neonatal mortality and its treatment is still challenging. OBJECTIVE: The study aimed to compare the effectiveness of nifedipine (Nif) with and without sildenafil citrate (SC) for the treatment of preterm labor in pregnant women. MATERIALS AND METHODS: In this clinical trial study, 126 pregnant women referred to the Fatemieh hospital, Hamadan, Iran with a complaint of preterm labor were evaluated. Participants were randomly divided into 2 groups of Nif 20 mg orally (single dose), then 10 mg every 6-hr, and at the same time vaginal SC 25 mg every 8 hr (Nif + SC) or Nif alone. Treatment was continued for 48-72 hr if uterine contractions did not resolve in both groups. Delivery rates at the time of hospitalization and neonatal outcome were compared between the 2 groups. RESULTS: No statistically significant difference was observed between the 2 study groups in terms of mean age, gestational age, body mass index, and parity. 76.2% of Nif + SC participants in the first 72 hr of hospitalization and 57.2% of Nif participants remained without delivery (p = 0.02). The neonatal hospitalization rate of the Nif + SC group in the neonatal intensive care unit was 25.4% and in the Nif group was 42.9% (p = 0.03). CONCLUSION: Nif with SC is superior to Nif alone in women at risk of preterm labor due to increasing gestational age and better neonatal outcomes.
Full text 13,350 characters · extracted from pmc-nxml · 2 sections · click to expand

Section

This study was funded by the Vice-Chancellor for Research and Technology of the Hamadan University of Medical Sciences, Hamadan, Iran (grand number: 140002281406). The authors thank Mr. Mohammad Faryadras for his benefit suggestion.

Coi Statement

The authors declare that there is no conflict of interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-07-13T06:13:37.491660+00:00
pubmed
last seen: 2026-07-13T06:12:31.500292+00:00
unpaywall
last seen: 2026-05-15T02:00:00.661756+00:00
License: CC-BY-NC-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine